CORZ slides over 5% as ongoing losses and bearish technical signals weigh on shares

Traders Union
All News
Stocks
Core scientific slides 5.32% today

Highlights

Core Scientific reported quarterly revenue of $164.2 million and a net loss of $1,081.1 million.
Shares of Core Scientific delivered a 38.4% loss for investors over the past year, including dividends.
Technical indicators show strong selling pressure with price action near session lows and a projected range of $11.45 to $13.67 for the next five sessions.

Investor losses deepen as weak results and contract gains diverge

Core Scientific reported quarterly revenue of $164.2 million along with a net loss of $1,081.1 million. The company also saw an increase in data center contracts in the latest period. Over the past year, investors holding the stock experienced a 38.4% loss including dividends, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent risks for Core Scientific. He notes continued net losses and a sharp yearly decline for shareholders. The price remains under its main moving averages, showing no sign of a reversal. Momentum and sentiment indicators both confirm the ongoing bearish outlook. "With fundamentals deteriorating and sellers dominating, I see little chance of a sustainable rebound in the near term."

Viktoras Karapetjanc, expert at Traders Union, focuses on contract growth and operational expansion as a positive driver. He believes the increased data center contracts offer a foundation for future revenue improvement. Despite current losses, he views the market setback as a potential accumulation opportunity for forward-looking investors. The expert expects sentiment to recover once volatility eases. "I see a chance for upside development if the company continues to secure new contracts and market conditions stabilize."

Jainam Mehta, market strategist, highlights the strong technical signals confirming downside momentum. He points out that price action remains within a defined volatility corridor, with support and resistance set at $11.45 and $13.67. Mehta sees potential for short-term tactical trades, especially if a range-bound pattern emerges. "A contrarian long could be considered only if the price holds above $11.45, but the prevailing trend favors defensive positioning."

Multi-timeframe selling signals as technical boundaries and volatility converge

Core Scientific is currently trading below the 20-day, 50-day, and 200-day moving averages ($14.51, $16.19, and $19.65, respectively), reaffirming active pressure from sellers across short-, medium-, and long-term trends. The Ichimoku Kijun at $15.34 remains well above the market, acting as a distant trend confirmation, with the near-term ceiling found at $12.67 and support at $11.45. Momentum indicators reflect persistent downside: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both flag strong selling signals, supported by the Commodity Channel Index (CCI) and Relative Strength Index (RSI) in “sell” territory. The Bull/Bear Power (BBP) shows sellers dominating intraday momentum and also notes an “oversold” forecast. The Stochastic RSI and Awesome Oscillator point to neutral conditions, indicating some divergence among oscillators. On the day, the stock declined to $12.56, down 5.32%, following a small upside gap of 0.38%. Price action sits near session lows with intraday volatility at 5.60%, reflecting renewed selling pressure after the open. These readings align with prevailing negative momentum.

Earlier, analysts noted that Core Scientific was exhibiting sustained technical weakness, with downside risks dominating its trend. The latest negative earnings and persistent selling momentum sharpen the bearish outlook, making a decisive move below $11.45 the key risk for further declines in the days ahead.

Source of Data: CORZ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.